Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNIGUIDE-2 phase 3 study of UBT251 versus semaglutide in type 2 diabetes mellitus inadequately controlled on metformin-based therapy
CTR20262543Phase 3Active
- Sponsor
- The United Laboratories International Holdings
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of UBT251, semaglutide in type 2 diabetes mellitus (T2DM), sponsored by The United Laboratories International Holdings. Started Jul 2026; status: active.
02
Drugs
UBT251semaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20262543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262543.